Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chiron Corporation
Phase III trial for meningococcal C vaccine begins
May 14th, 2003
Chiron Corporation (CHIR) announced that it has initiated a phase III trial in the United States for Menjugate, the company's conjugated vaccine for the prevention of meningococcal C disease. The study, which is being conducted in conjunction with the Northern California Kaiser Permanente Vaccines Research Center, will expand the vaccine's safety database for a U.S. population relative to the safety profile of the current U.S.-licensed meningococcal polysaccharide vaccine Menomune (A, C, Y, W-135). "Bringing Menjugate to the United States would help physicians and families prevent one of this country's most common forms of meningococcal disease,...
Source: Biotech Week (2003-05-14)
|
